Observational studyEmergency medicine Australasia : EMA2026
Intranasal Dexmedetomidine for Paediatric Procedural Sedation in the Emergency Department: A Single-Centre Retrospective Observational Cohort Study.
Observational study in Emergency medicine Australasia : EMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo describe the use, effectiveness and safety of intranasal dexmedetomidine (IN DEX) for ED paediatric procedural sedation.
methodA retrospective cohort study was conducted over 7 months following implementation of an IN DEX guideline at Townsville University Hospital ED. Children aged 1-16 years were eligible if they received IN DEX. Outcomes of interest were sedation depth, ED length of stay (EDLOS), adverse events, procedural success and clinician/carer satisfaction.
resultsA total of 114 patients were recruited. Median age was 3 years (IQR 2-5), 55.3% were male and 31.6% were Aboriginal and/or Torres Strait Islander children. Median IN DEX dose was 3.11 mcg/kg (IQR 2.81-3.93). Common indications included peripheral intravenous cannulation (35.1%), laceration repair (21.1%), burns care (13.2%), foreign body removal (11.4%) and medical imaging (8.8%). Median EDLOS was 395 min (IQR 255-579). Sedation depth was moderate (mean University Michigan Sedation Scale score 2.1 (SD 0.9), a 0-4 scale on which higher scores indicate deeper sedation; documented for 90 of 114 sedations). IN DEX was successful as a sole sedative agent in 78.1% (95% CI 69.6%-84.7%) patients, ranging from 90.0% (9/10) for medical imaging to 53.8% (7/13) for foreign body removal. Adverse events occurred in 13.2% of patients (95% CI 8.1%-20.6%), predominantly mild bradycardia. Younger age was associated with higher success rates (aOR 0.86 per year, 95% CI 0.74-0.998). No dose-response relationship was identified. Clinicians (mean 4.3/5) and parents (mean 4.5/5) reported high satisfaction, although satisfaction was documented for fewer than half of sedations and significantly more often when sedation succeeded.
conclusionIn our single-centre study IN DEX is a well-tolerated, moderately effective and safe agent for ED paediatric procedural sedation with higher success rates in younger patients. Large, prospective, multisite studies are necessary to establish IN DEX's safety, effectiveness and predictors of success.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.